PRKAB1 and metabolic dysfunction-associated steatotic liver disease: In the context of MASLD, hepatic AMPK activity is significantly reduced, while AMPK activation can ameliorate multiple pathological processes including lipid metabolism, inflammatory response, and fibrosis (7).